International Journal of Biochemistry, Biophysics & Molecular Biology

| Peer-Reviewed |

"First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso "

Received: May 14, 2019    Accepted: Jun. 17, 2019    Published: Jun. 28, 2019
Views:       Downloads:

Share This Article

Abstract

Resistance to a wide variety of common antimicrobials is observed among clinical strains designated as extended-spectrum β-lactamase (ESBL) producers. They produce enzymatic proteins that effectively inactivate cephalosporins and aztreonam and are a serious global health problem that complicates treatment strategies. Many studies report a high prevalence of ESBL producers among Gram-negative bacilli. The purpose of this work was to identify of PER resistance gene in enterobacterial strains. Gram-negative bacilli resistant to at least one third-generation cephalosporin, Aztreonam or showing a synergistic image between amoxicillin + clavulanic acid and a third generation cephalosporin were isolated during an antibiogram. Antibiotic resistance was detected for the following antibiotics: Ceftriaxone, Cefotaxime, Ceftazidime and Aztreonam. A classical polymerase chain reaction (PCR) analysis of the β-lactamase PER (Pseudomonas Extended Resistance) gene was performed using specific primers in 60 ESBL-producing isolates. Among 250 strains of Gram negative bacilli collected, 60 strains (24%) showed resistance to antibiotics used. Stool samples are a major source of ESBL producers. The highest prevalence of resistant strains was observed in Escherichia coli with a rate of 35%. Among the producers of ESBL isolates, the presence of the PER gene was detected in the present study by up to 15% in 6 bacterial species. This study represents the first detection of the PER gene in Burkina Faso.

DOI 10.11648/j.ijbbmb.20190401.12
Published in International Journal of Biochemistry, Biophysics & Molecular Biology ( Volume 4, Issue 1, June 2019 )
Page(s) 7-12
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Broad-spectrum Beta-lactamases (ESBL), PER Gene, PCR

References
[1] D. L. Monnet, “Consommation d’antibiotiques et résistance bactérienne,” in Annales françaises d’anesthésie et de réanimation, 2000, vol. 19, no. 5, pp. 409–417.
[2] A. Ouedraogo, “Prévalence, circulation et caractérisation des bactéries multirésistantes au Burkina Faso To cite this version : HAL Id : tel-01476152 Spécialité : Biologie Santé,” 2017.
[3] E. Lecaillon et al., “Emergence de Proteus mirabilis et Klebsiella pneumoniae possédant une BLSE: traitement et suivi,” Médecine Mal. Infect., vol. 23, pp. 427–430, 1993.
[4] P. Charlier, “Résistance bactérienne aux B-lactamines,” Medecine/Science, vol. 14, no. lipide II, pp. 544–555, 1998.
[5] V. Cattoir, “LES NOUVELLES BETA-LACTAMASES A SPECTRE ETENDU (BLSE),” 2008.
[6] D. Vodovar, G. Marcadé, L. Raskine, I. Malissin, and B. Mégarbane, “Entérobactéries productrices de bêta-lactamases à spectre élargi: épidémiologie, facteurs de risque et mesures de prévention,” La Rev. Médecine Interne, vol. 34, no. 11, pp. 687–693, 2013.
[7] K. J. Zongo, A. M. Dabire, L. G. Compaore, I. Sanou, L. Sangare, and J. Simpore, “First detection of bla TEM, SHV and CTX-M among Gram negative bacilli exhibiting extended spectrum β - lactamase phenotype isolated at University Hospital Center, Yalgado Ouedraogo, Ouagadougou, Burkina,” vol. 14, no. 14, pp. 1174–1180, 2015.
[8] V. Jarlier, M. Nicolas, G. Fournier, and A. Philippon, “Extended Broad-Spectrum ~ -Lactamases Conferring Transferable Resistance to Newer ~ -Lactam Agents in Enterobacteriaceae : Hospital Prevalence and Susceptibility Patterns,” vol. 10, no. 4, pp. 867–878, 1988.
[9] H. Harbottle, S. Thakur, S. Zhao, and D. G. White, “Genetics of Antimicrobial Resistance,” Anim. Biotechnol., vol. 17, no. 2, pp. 111–124, Dec. 2006.
[10] P. Boerlin and R. J. Reid-Smith, “Antimicrobial resistance: its emergence and transmission,” Anim. Heal. Res. Rev., vol. 9, no. 2, pp. 115–126, 2008.
[11] A. Philippon and G. Arlet, “[Beta-lactamases of Gram negative bacteria: never-ending clockwork!],” Ann. Biol. Clin. (Paris)., vol. 64, no. 1, pp. 37–51, 2006.
[12] P. Feglo et al., “Emergence of a Novel Extended-Spectrum- ␤ -Lactamase (ESBL) - Pathogenic Escherichia coli in Kumasi, Ghana,” vol. 51, no. 2, pp. 728–730, 2013.
[13] A. Muylaert and J. G. Mainil, “Résistances bactériennes aux antibiotiques : les mécanismes et leur « contagiosité »,” pp. 109–123, 2012.
[14] T. Kubo et al., “Corrigendum to ‘Occurrence of infection following prostate biopsy procedures in Japan : Japanese Research Group for Urinary Tract Infection (JRGU) e A multi-center retrospective study’ [J Infect Chemother 20 (2014) 232 e 237],” J. Infect. Chemother., vol. 20, no. 10, p. 660, 2014.
[15] R. Nugent and I. N. Okeke, “Editorial When medicines fail : recommendations for curbing antibiotic resistance,” 2010.
[16] P. Herindrainy, R. Ratovoson, and E. R. Hariniana, “Rectal Carriage of Extended-Spectrum Beta-Lactamase-Producing Gram- Rectal Carriage of Extended-Spectrum Beta-Lactamase- Producing Gram-Negative Bacilli in Community Settings in Madagascar,” no. November 2017, pp. 8–10, 2011.
[17] S. Sirinavin and S. F. Dowell, “Antimicrobial resistance in countries with limited resources: unique challenges and limited alternatives,” Semin. Pediatr. Infect. Dis., vol. 15, no. 2, pp. 94–98, 2004.
[18] J. G. Pieboji, “CARACTÉRISATION DES BETA-LACTAMASES ET LEUR INHIBITION PAR LES EXTRAITS DE PLANTES MÉDICINALES,” 2007.
[19] C. Zhuo, X. Li, Z. Zong, and N. Zhong, “Epidemic Plasmid Carrying bla CTX-M-15 in Klebsiella penumoniae in China,” vol. 8, no. 1, pp. 1–8, 2013.
[20] A. Mètuor-dabiré, “Caractérisations moléculaire et cinétique des types de β-lactamases à spectre élargi (BLSE) de souches bactériennes collectées au Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle (CHUP-CDG) de Ouagadougou,” Thèse Présentée pour obtenir le grade Docteur l ’ Univ. Ouagadougou, 2014.
[21] P. Nordmann, E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia, “Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa,” Antimicrob. Agents Chemother., vol. 37, no. 5, pp. 962–969, May 1993.
[22] P. Nordmannl, T. Naas, S. De Microbiologie, H. R. Poincare, and F. D. M. Paris-ouest, “Sequence Analysis of PER-1 Extended-Spectrum Comparison with Class A 13-Lactamases,” vol. 38, no. 1, pp. 104–114, 1994.
[23] H. Vahaboglu et al., “Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study,” Antimicrob. Agents Chemother., vol. 41, no. 10, pp. 2265–2269, Oct. 1997.
[24] G. Bahar, B. Eraç, A. Mert, and Z. Gülay, “PER-1 Production in a Urinary Isolate of Providencia rettgeri,” J. Chemother., vol. 16, no. 4, pp. 343–346, Aug. 2004.
[25] D. Yong et al., “High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp. in Korea,” Antimicrob. Agents Chemother., vol. 47, no. 5, pp. 1749–1751, May 2003.
[26] L. Pagani et al., “Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy,” J. Clin. Microbiol., vol. 42, no. 6, pp. 2523–2529, Jun. 2004.
[27] M. PEREIRA et al., “PER-1 Extended-Spectrum β-Lactamase Production in an Alcaligenes faecalis Clinical Isolate Resistant to Expanded-Spectrum Cephalosporins and Monobactams from a Hospital in Northern Italy,” Microb. Drug Resist. vol. 6, no. 1, pp. 85–90, Jan. 2000.
Cite This Article
  • APA Style

    Rahimatou Yasmine Tiemtoré, Amana Mètuor-Dabiré, Theodora Mahoukèdè Zohoncon, Yasmine Aminata Bangré, Serge Sougue, et al. (2019). "First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso ". International Journal of Biochemistry, Biophysics & Molecular Biology, 4(1), 7-12. https://doi.org/10.11648/j.ijbbmb.20190401.12

    Copy | Download

    ACS Style

    Rahimatou Yasmine Tiemtoré; Amana Mètuor-Dabiré; Theodora Mahoukèdè Zohoncon; Yasmine Aminata Bangré; Serge Sougue, et al. "First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso ". Int. J. Biochem. Biophys. Mol. Biol. 2019, 4(1), 7-12. doi: 10.11648/j.ijbbmb.20190401.12

    Copy | Download

    AMA Style

    Rahimatou Yasmine Tiemtoré, Amana Mètuor-Dabiré, Theodora Mahoukèdè Zohoncon, Yasmine Aminata Bangré, Serge Sougue, et al. "First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso ". Int J Biochem Biophys Mol Biol. 2019;4(1):7-12. doi: 10.11648/j.ijbbmb.20190401.12

    Copy | Download

  • @article{10.11648/j.ijbbmb.20190401.12,
      author = {Rahimatou Yasmine Tiemtoré and Amana Mètuor-Dabiré and Theodora Mahoukèdè Zohoncon and Yasmine Aminata Bangré and Serge Sougue and Jacob Zongo and Jacques Simpore},
      title = {"First Detection of PER-Type Extended-Spectrum  β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso "},
      journal = {International Journal of Biochemistry, Biophysics & Molecular Biology},
      volume = {4},
      number = {1},
      pages = {7-12},
      doi = {10.11648/j.ijbbmb.20190401.12},
      url = {https://doi.org/10.11648/j.ijbbmb.20190401.12},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ijbbmb.20190401.12},
      abstract = {Resistance to a wide variety of common antimicrobials is observed among clinical strains designated as extended-spectrum β-lactamase (ESBL) producers. They produce enzymatic proteins that effectively inactivate cephalosporins and aztreonam and are a serious global health problem that complicates treatment strategies. Many studies report a high prevalence of ESBL producers among Gram-negative bacilli. The purpose of this work was to identify of PER resistance gene in enterobacterial strains. Gram-negative bacilli resistant to at least one third-generation cephalosporin, Aztreonam or showing a synergistic image between amoxicillin + clavulanic acid and a third generation cephalosporin were isolated during an antibiogram. Antibiotic resistance was detected for the following antibiotics: Ceftriaxone, Cefotaxime, Ceftazidime and Aztreonam. A classical polymerase chain reaction (PCR) analysis of the β-lactamase PER (Pseudomonas Extended Resistance) gene was performed using specific primers in 60 ESBL-producing isolates. Among 250 strains of Gram negative bacilli collected, 60 strains (24%) showed resistance to antibiotics used. Stool samples are a major source of ESBL producers. The highest prevalence of resistant strains was observed in Escherichia coli with a rate of 35%. Among the producers of ESBL isolates, the presence of the PER gene was detected in the present study by up to 15% in 6 bacterial species. This study represents the first detection of the PER gene in Burkina Faso.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - "First Detection of PER-Type Extended-Spectrum  β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso "
    AU  - Rahimatou Yasmine Tiemtoré
    AU  - Amana Mètuor-Dabiré
    AU  - Theodora Mahoukèdè Zohoncon
    AU  - Yasmine Aminata Bangré
    AU  - Serge Sougue
    AU  - Jacob Zongo
    AU  - Jacques Simpore
    Y1  - 2019/06/28
    PY  - 2019
    N1  - https://doi.org/10.11648/j.ijbbmb.20190401.12
    DO  - 10.11648/j.ijbbmb.20190401.12
    T2  - International Journal of Biochemistry, Biophysics & Molecular Biology
    JF  - International Journal of Biochemistry, Biophysics & Molecular Biology
    JO  - International Journal of Biochemistry, Biophysics & Molecular Biology
    SP  - 7
    EP  - 12
    PB  - Science Publishing Group
    SN  - 2575-5862
    UR  - https://doi.org/10.11648/j.ijbbmb.20190401.12
    AB  - Resistance to a wide variety of common antimicrobials is observed among clinical strains designated as extended-spectrum β-lactamase (ESBL) producers. They produce enzymatic proteins that effectively inactivate cephalosporins and aztreonam and are a serious global health problem that complicates treatment strategies. Many studies report a high prevalence of ESBL producers among Gram-negative bacilli. The purpose of this work was to identify of PER resistance gene in enterobacterial strains. Gram-negative bacilli resistant to at least one third-generation cephalosporin, Aztreonam or showing a synergistic image between amoxicillin + clavulanic acid and a third generation cephalosporin were isolated during an antibiogram. Antibiotic resistance was detected for the following antibiotics: Ceftriaxone, Cefotaxime, Ceftazidime and Aztreonam. A classical polymerase chain reaction (PCR) analysis of the β-lactamase PER (Pseudomonas Extended Resistance) gene was performed using specific primers in 60 ESBL-producing isolates. Among 250 strains of Gram negative bacilli collected, 60 strains (24%) showed resistance to antibiotics used. Stool samples are a major source of ESBL producers. The highest prevalence of resistant strains was observed in Escherichia coli with a rate of 35%. Among the producers of ESBL isolates, the presence of the PER gene was detected in the present study by up to 15% in 6 bacterial species. This study represents the first detection of the PER gene in Burkina Faso.
    VL  - 4
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso; Department of Biochemistry-Microbiology, University of Dédougou, Dédougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso

  • Section